Armata Pharmaceuticals, Inc. (ARMP) FinancialsARMPArmata Pharmaceuticals, Inc.

Evaluating the bottom line, Armata Pharmaceuticals, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -410.84%, while the net margin is 2953.82%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ARMP converts its operational activities into shareholder value.

In the context of the broader market, ARMP competes directly with industry leaders such as HURA and FHTX. With a market capitalization of $111.54M, it holds a significant position in the sector. When comparing efficiency, ARMP's gross margin of 100.00% stands against HURA's N/A and FHTX's 100.00%. Such benchmarking helps identify whether Armata Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Armata Pharmaceuticals has reported a gross margin of 100% consistently, but it has also faced significant net income losses, with a staggering net loss of $124.3 million in Q4 2025 and $115.3 million in Q1 2026. The current ratio is low at 0.11, indicating liquidity issues.